2cureX AB (OSTO:2CUREX) Debt-to-Asset : 0.00 (As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is 2cureX AB Debt-to-Asset?

2cureX AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was kr0.00 Mil. 2cureX AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was kr0.00 Mil. 2cureX AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was kr21.48 Mil. 2cureX AB's debt to asset for the quarter that ended in Sep. 2023 was 0.00.

2cureX AB Debt-to-Asset Historical Data

The historical data trend for 2cureX AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2cureX AB Debt-to-Asset Chart

2cureX AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

2cureX AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of 2cureX AB's Debt-to-Asset

For the Biotechnology subindustry, 2cureX AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

2cureX AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 2cureX AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where 2cureX AB's Debt-to-Asset falls into.

2cureX AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

2cureX AB's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	47.657
	=	0.00

2cureX AB's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	21.483
	=	0.00

2cureX AB (OSTO:2CUREX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

2cureX AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of 2cureX AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

2cureX AB (OSTO:2CUREX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2cureX AB (OSTO:2CUREX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

2QE:Germany

Address

Fruebjergvej 3, Copenhagen, DNK, DK-2100

Website

https://www.2curex.com

2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.

2cureX AB (OSTO:2CUREX) Headlines

No Headlines